SD - GE HealthCare Technologies Inc. (0001932393) (Filer)

SCHEDULE 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

SCHEDULE 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

8-K - GE HealthCare Technologies Inc. (0001932393) (Filer)

10-Q - GE HealthCare Technologies Inc. (0001932393) (Filer)

8-K - GE HealthCare Technologies Inc. (0001932393) (Filer)

SCHEDULE 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

DEFA14A - GE HealthCare Technologies Inc. (0001932393) (Filer)

DEF 14A - GE HealthCare Technologies Inc. (0001932393) (Filer)

8-K - GE HealthCare Technologies Inc. (0001932393) (Filer)

BMO Capital Markets initiated coverage of GE HealthCare with a rating of Market Perform and set a new price target of $70.00

RBC Capital Mkts initiated coverage of GE HealthCare with a rating of Outperform and set a new price target of $80.00

UBS upgraded GE HealthCare from Sell to Neutral and set a new price target of $69.00

Goldman downgraded GE HealthCare from Buy to Neutral and set a new price target of $65.00

UBS downgraded GE HealthCare from Neutral to Sell and set a new price target of $77.00

Barclays initiated coverage of GE HealthCare with a rating of Equal Weight and set a new price target of $86.00

Citigroup downgraded GE HealthCare from Buy to Neutral and set a new price target of $83.00

UBS upgraded GE HealthCare from Sell to Neutral and set a new price target of $73.00

Goldman upgraded GE HealthCare from Neutral to Buy and set a new price target of $100.00 from $85.00 previously

Jefferies upgraded GE HealthCare from Hold to Buy and set a new price target of $103.00 from $95.00 previously

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

MIM Anyware is designed to deliver secure, healthcare system-controlled access to the full portfolio of GE HealthCare’s MIM software solutions through a web browser, regardless of their location. The platform enables simultaneous clinical review and processing of imaging data across departments to enhance clinical collaboration and patient care delivery. GE HealthCare (NASDAQ:GEHC) today announced the introduction of MIM Anyware™, a remote access platform that provides secure, healthcare system-controlled access to imaging data through a web browser without requiring local software installation. By enabling authorized users to access MIM software applications from virtually any locat

More than 1,300 pieces of technology to be added across Catholic Health hospitals and ambulatory locations, expanding access to advanced imaging, diagnostics and specialized care closer to home AI-powered technologies to support scheduling, operations, diagnostics, and monitoring across on-device, departmental and enterprise-level applications 10-year Care Alliance combines technology modernization with service support designed to help improve equipment reliability, operational efficiencies and care consistency across Catholic Health Catholic Health, an integrated health system located on Long Island, NY, and GE HealthCare (NASDAQ:GEHC) announced today a 10-year strategic partners

A novel theranostics study explores imaging- and data-informed approaches to support individualized treatment decisions and expand access to theranostics Collaboration stems from a 2023 Strategic Radiology Research Alliance between Mayo Clinic and GE HealthCare, aimed at transforming the experience of patients and clinicians in the practice of radiology and the delivery of novel therapies GE HealthCare and Mayo Clinic today announced the MI-BET (Molecular Imaging Biomarker-Based End of Therapy Trial) research collaboration, a novel theranostics study designed to explore a more personalized approach to radioligand therapy (RLT) for patients with advanced prostate cancer. This collabor

GE HealthCare (NASDAQ:GEHC) will announce its second quarter 2026 financial results before the market opens on Wednesday, July 29, 2026. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also will be posted at the same link on the GE HealthCare Investor Relations website. About GE HealthCare Technologies Inc. GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutic

The Board of Directors of GE HealthCare Technologies Inc. (NASDAQ:GEHC) today declared a cash dividend of $0.035 per share of Common Stock for the second quarter of 2026 payable on August 14, 2026, to all shareholders of record as of July 24, 2026.About GE HealthCare Technologies Inc.GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world’s most complex diseases. Serving patients and providers for 130 years, GE HealthCare is delivering bold innovations designed for the next era of medicine across its Advanced Imaging Solutions, Patient Care Solutions,

Upgrade capabilities are designed to help health systems harness the latest Allia™ innovations while maximizing existing infrastructure investments GE HealthCare today announced Allia™ platform upgrade pathways designed to help customers modernize select legacy Innova™ and Discovery™ Image Guiding Solutions (IGS) systems. These pathways provide access to Allia technologies and workflows that support efficiency and procedural decision-making while helping preserve existing infrastructure, avoid major construction work, extend interventional room lifetime, and minimize disruption to clinical operations. As procedural complexity and patient volumes grow and installed systems age, healthc

GE HealthCare to showcase cloud-enabled solutions including Genesis Radiology Workspace and InteleShare at SIIM 2026 Enterprise imaging solutions are designed to help improve workflow and productivity, enabling better patient care GE HealthCare will showcase its latest enterprise imaging solutions at the Society for Imaging Informatics in Medicine (SIIM) 2026 Annual Meeting in Pittsburgh, PA. Medical imaging departments today are under immense pressure from all sides including rising imaging volumes and increasing case complexity, while staffing shortages continue to grow. According to the American College of Radiology (ACR), radiologist workforce shortages have been identified as

Marking the evolution of MIM AI-enabled auto-contouring software, MIM Contour ProtégéAI+ 2.0 introduces new models, including a Magnetic Resonance (MR) Brain model, as well as an updated Computed Tomography (CT) Male Pelvis model, expanding clinical capabilities across key anatomical regions. GE HealthCare will showcase MIM Contour ProtégéAI+ 2.0 at booth #202 during the American Association of Medical Dosimetrists 51st Annual Meeting taking place June 7-10, 2026 in Orlando, Florida. GE HealthCare (NASDAQ:GEHC) today announced it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for MIM Contour ProtégéAI+™ 2.0, an AI-enabled auto-contouring softw

Issued on behalf of Ventripoint Diagnostics Ltd.A Toronto-based small-cap is converting clinical validation into real-world hospital deployments at the moment AI cardiac imaging procurement is reorganizing globallyNEW YORK, May 19, 2026 /CNW/ -- USA News Group News Commentary — Cardiology has become one of the proving grounds for medical artificial intelligence, and the procurement environment around it has shifted hard in the last twelve months. Hospital networks are no longer content to evaluate clinical accuracy in isolation; they want department-level economic proof before they sign deployment contracts. That shift is reshaping which AI imaging companies can convert pilot data into recur

The company will showcase the latest iRT solution, MIM software innovations, and BK Medical technology – advancing speed, connectivity, and personalized medicine across the cancer care pathway. At the European Society for Radiotherapy and Oncology (ESTRO) 2026 Congress in Stockholm, GE HealthCare (NASDAQ:GEHC) will highlight a portfolio of AI-enabled solutions designed to support clinicians across radiation therapy, theranostics, and image-guided interventions. The company's presence underscores its focus on reducing workflow complexity, improving coordination across departments, and enabling more timely and personalized cancer care. According to the World Health Organization, cancer

GE HealthCare (NASDAQ:GEHC) announced today the appointment of Kevin A. Lobo, Chair and Chief Executive Officer of Stryker Corporation (NYSE:SYK), to its Board of Directors effective March 13. Mr. Lobo brings more than 25 years of medical technology, operational, and financial leadership experience. His clinical expertise and track record of driving innovation and scaling global businesses make him well qualified to contribute to GE HealthCare's strategic priorities. "Kevin is a seasoned healthcare executive with a deep understanding of the medical technology landscape. His knowledge and insight will further strengthen our Board as we continue to build a more personalized, connected and s

BOCA RATON, Fla., June 2, 2025 /PRNewswire/ -- PharmaLogic Holdings Corp. ("PharmaLogic" or "the Company"), a leading contract development and manufacturing organization (CDMO) specialized in radiopharmaceuticals, today announces the Company has appointed Etienne Montagut, currently serving as President, to the position of President and Chief Executive Officer, effective as of 1 June 2025. Mr. Montagut brings over 25 years of senior leadership experience in the pharmaceutical sector, with a solid track record of driving growth and executing strategic transformation across glob

GE HealthCare (NASDAQ:GEHC), a leading global healthcare solutions provider, announced the appointment of Jeannette Bankes as president and CEO, Patient Care Solutions, effective May 1, 2025. Peter Arduini, president and CEO, GE HealthCare, said, "Jeannette is a proven leader who has diverse and deep experience at publicly traded companies in the healthcare industry. We proudly welcome her to the company and are confident that she has the expertise to move Patient Care Solutions forward and deliver on our precision care strategy." Bankes brings with her three decades of global experience including product management, marketing, sales, regulatory, medical affairs, and operations and manufa

Collaboration has always been important in the healthcare industry, but in this era of digital health, teamwork across institutions has become essential Enhancing Elekta's radiation therapy offerings with GE HealthCare's MIM Software medical imaging management solutions will help drive greater benefits for global healthcare systems This new collaboration complements GE HealthCare and Elekta's existing global commercial collaboration agreement, which enables the two companies to provide hospitals and cancer patients a comprehensive radiation therapy offering across imaging and treatment Weeks after closing its acquisition of MIM Software – a global provider of medical imaging analy

SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

GE HealthCare (NASDAQ:GEHC) will announce its second quarter 2026 financial results before the market opens on Wednesday, July 29, 2026. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also will be posted at the same link on the GE HealthCare Investor Relations website. About GE HealthCare Technologies Inc. GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutic

The Board of Directors of GE HealthCare Technologies Inc. (NASDAQ:GEHC) today declared a cash dividend of $0.035 per share of Common Stock for the second quarter of 2026 payable on August 14, 2026, to all shareholders of record as of July 24, 2026.About GE HealthCare Technologies Inc.GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world’s most complex diseases. Serving patients and providers for 130 years, GE HealthCare is delivering bold innovations designed for the next era of medicine across its Advanced Imaging Solutions, Patient Care Solutions,

Revenue growth of 7.4%, including Organic revenue growth* of 2.9% Total orders up 1.1% organically versus 10.3% growth in the year-ago period; book-to-bill of 1.07 times and backlog of $21.8 billion Profitability in the quarter was impacted by a discrete PDx supplier issue that has since been resolved Net income margin of 7.6% and Adjusted earnings before interest and taxes (EBIT) margin* of 13.5%; diluted earnings per share (EPS) of $0.85 and Adjusted EPS* of $0.99 Cash flow from operating activities of $290 million and Free cash flow* of $112 million For the full-year 2026, Company reaffirms topline growth driven by healthy global end market demand; reduces profit and Free

GE HealthCare (NASDAQ:GEHC) will announce its first quarter 2026 financial results before the market opens on Wednesday, April 29, 2026. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also will be posted at the same link on the GE HealthCare Investor Relations website. About GE HealthCare Technologies Inc. GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutic

Expands GE HealthCare's enterprise imaging footprint by delivering comprehensive, end‑to‑end solutions across ambulatory, teleradiology, and hospital care settings Advances GE HealthCare's D3 strategy by accelerating the development of disease‑focused smart devices and solutions enabled by digital (cloud and software) and artificial intelligence (AI) capabilities Enhances a fully connected, cloud‑first imaging ecosystem with an expanded GE HealthCare portfolio of AI, digital tools, and SaaS offerings designed to improve clinical operations Tuck‑in acquisition expected to strengthen the Imaging portfolio, increase recurring revenue mix, and support sustainable top‑line growth and p

The Board of Directors of GE HealthCare Technologies Inc. (NASDAQ:GEHC) today declared a cash dividend of $0.035 per share of Common Stock for the first quarter of 2026 payable on May 15, 2026, to all shareholders of record as of April 3, 2026. About GE HealthCare Technologies Inc. GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world's most complex diseases. Serving patients and providers for 130 years, GE HealthCare is delivering bold innovations designed for the next era of medicine across its Imaging, Advanced Visualization Solutions, Patie

Company exceeds topline and earnings per share expectations; demonstrates operational resilience Fourth quarter 2025 highlights(1) Revenue growth of 7.1%, including Organic revenue growth* of 4.8%, driven primarily by the U.S. and Europe, the Middle East and Africa (EMEA) Net income margin of 10.3% and Adjusted earnings before interest and taxes (EBIT) margin* of 16.7% Diluted earnings per share (EPS) of $1.29 and Adjusted EPS* of $1.44 Cash flow from operating activities of $1.0 billion and Free cash flow* of $916 million Full year 2025 highlights(1) Revenue growth of 4.8%, including Organic revenue growth* of 3.5% Organic orders growth of 5.2% Net income margin o

GE HealthCare (NASDAQ:GEHC) will announce its fourth quarter and full year 2025 financial results before the market opens on Wednesday, February 4, 2026. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also will be posted at the same link on the GE HealthCare Investor Relations website. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innova

The Board of Directors of GE HealthCare Technologies Inc. (NASDAQ:GEHC) today declared a cash dividend of $0.035 per share of Common Stock for the fourth quarter of 2025 payable on February 13, 2026, to all shareholders of record as of January 9, 2026. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for mo

Revenue growth was 6% and Organic revenue growth* was 4% year-over year, driven by Europe, the Middle East and Africa (EMEA) and the U.S. Organic orders growth was 6% with growth across all segments Net income margin was 8.7%; Adjusted earnings before interest and taxes (EBIT) margin* was 14.8% Diluted earnings per share (EPS) were $0.98; Adjusted EPS* was $1.07 Cash flow from operating activities was $593 million; Free cash flow* was $483 million Excluding tariff impacts, margin and EPS would have exceeded prior year Raises the lower end of full-year 2025 Adjusted EPS* guidance range and reaffirms all other metrics GE HealthCare (NASDAQ:GEHC) today reported fina